(Z)-N-(1-Chloro-1-(4-methoxyphenyl)-3-oxo-3-(piperidin-1-yl)prop-1-en-2-yl)benzamide

Catalog No. :
ACIBLS365
CAS No. :
1323140-64-2
Molecular Formula :
C22H23ClN2O3
Molecular Weight :
398.89

IUPAC Name:(Z)-N-(1-chloro-1-(4-methoxyphenyl)-3-oxo-3-(piperidin-1-yl)prop-1-en-2-yl)benzamide

(Z)-N-(1-Chloro-1-(4-methoxyphenyl)-3-oxo-3-(piperidin-1-yl)prop-1-en-2-yl)benzamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g95%$429.00Login to see priceInquiryInquiry
5g95%$1411.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(Z)-N-(1-Chloro-1-(4-methoxyphenyl)-3-oxo-3-(piperidin-1-yl)prop-1-en-2-yl)benzamide
IUPAC Name(Z)-N-(1-chloro-1-(4-methoxyphenyl)-3-oxo-3-(piperidin-1-yl)prop-1-en-2-yl)benzamide
Molecular FormulaC22H23ClN2O3
Molecular Weight398.89
SMILESO=C(N/C(C(N1CCCCC1)=O)=C(Cl)/C2=CC=C(OC)C=C2)C3=CC=CC=C3
InChI KeyFAZSNTAOGNSKDI-VXPUYCOJSA-N
Synonym(Z)-N-(1-chloro-1-(4-methoxyphenyl)-3-oxo-3-(piperidin-1-yl)prop-1-en-2-yl)benzamide;Benzamide, N-[(1Z)-2-chloro-2-(4-methoxyphenyl)-1-(1-piperidinylcarbonyl)ethenyl]-
CAS No.1323140-64-2

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACIBLS365 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACIBLS365 route product structure diagram
    ACIBLS3651323140-64-2
Inquiry

2. ACIBLS365 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACIBLS365 route product structure diagram
    ACIBLS3651323140-64-2
Inquiry

Comments (0)